Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension
Xiang-Yu Ji,Cheng-Jing Lei,Shuang Kong,Han-Fei Li,Si-Yu Pan,Yu-Jing Chen,Fan-Rong Zhao,Tian-Tian Zhu
DOI: https://doi.org/10.2147/dddt.s439686
IF: 4.3188
2024-02-20
Drug Design Development and Therapy
Abstract:Xiang-Yu Ji, 1– 3 Cheng-Jing Lei, 2, 3 Shuang Kong, 2, 3 Han-Fei Li, 2, 3 Si-Yu Pan, 2, 3 Yu-Jing Chen, 2, 3 Fan-Rong Zhao, 2, 3 Tian-Tian Zhu 1– 3 1 Department of Pharmacy, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, People's Republic of China; 2 College of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, People's Republic of China; 3 Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, Henan, People's Republic of China Correspondence: Tian-Tian Zhu, College of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, 453003, People's Republic of China, Tel +86 15225990135, Email Purpose: The underlying causes of pulmonary arterial hypertension (PAH) often remain obscure. Addressing PAH with effective treatments presents a formidable challenge. Studies have shown that Hydroxysafflor yellow A (HSYA) has a potential role in PAH, While the mechanism underlies its protective role is still unclear. The study was conducted to investigate the potential mechanisms of the protective effects of HSYA. Methods: Using databases such as PharmMapper and GeneCards, we identified active components of HSYA and associated PAH targets, pinpointed intersecting genes, and constructed a protein-protein interaction (PPI) network. Core targets were singled out using Cytoscape for the development of a model illustrating drug-component-target-disease interactions. Intersection targets underwent analysis for Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Selected components were then modeled for target interaction using Autodock and Pymol. In vivo validation in a monocrotaline-induced PAH (MCT-PAH) animal model was utilized to substantiate the predictions made by network pharmacology. Results: We associated HSYA with 113 targets, and PAH with 1737 targets, identifying 34 mutual targets for treatment by HSYA. HSYA predominantly affects 9 core targets. Molecular docking unveiled hydrogen bond interactions between HSYA and several PAH-related proteins such as ANXA5, EGFR, SRC, PPARG, PGR, and ESR1. Conclusion: Utilizing network pharmacology and molecular docking approaches, we investigated potential targets and relevant human disease pathways implicating HSYA in PAH therapy, such as the chemical carcinogenesis receptor activation pathway and the cancer pathway. Our findings were corroborated by the efficacious use of HSYA in an MCT-induced rat PAH model, confirming its therapeutic potential. Keywords: network pharmacology, molecular docking, hydroxy-safflower yellow A, pulmonary arterial hypertension Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder marked by high pressures in the pulmonary arteries, which can lead to serious health consequences and decreased patient survival. 1 The 6th World Symposium on Pulmonary Hypertension and subsequent updates to the 2022 guidelines have revised the hemodynamic definition of PAH to enhance diagnosis and treatment modalities. These guidelines now specify that normal pulmonary vascular resistance (PVR) should not exceed 2 Wood Units (WU), and differentiate pre-capillary PAH as having a PVR greater than 2 WU. A mean pulmonary artery pressure over 20 mm Hg coupled with a PVR above 2 WU are the updated criteria for diagnosing PAH. 2 Patients diagnosed with PAH exhibit sustained pulmonary artery pressure, which contributes to detrimental structural alterations and a rise in resistance within the pulmonary vascular system—a phenomenon known as pulmonary vascular remodeling. 3,4 As a result, the right ventricle faces a heightened workload that, without appropriate adaptation of the pulmonary arteries, triggers an escalation in PVR and ultimately progresses toward heart failure. 5,6 The complexity of PAH's pathophysiology, often exacerbated by its association with other health conditions, and a rising incidence and prevalence of idiopathic and hereditary forms—estimated at 5 to 25 cases per million individuals—present significant obstacles in clinical management. 7 Although a study of 2967 US patients showed improved 1, 3, 5, and 7-year survival rates at 91%, 85%, 68%, and 49% respectively, PAH remains a grave concern with a heavy symptom burden and poor long-term prognosis, emphasizing the urgency for advanced research into the pathogenic mechanisms driving PAH. 8,9 Despite progress in our understanding and treatment of this condition, current therapies fall short in halting the relentless progression of pulmonary vascular remodel -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal